Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:35:57 EDT Thu 16 Oct 2025
Enter Symbol
or Name
USA
CA



Q:BLRX - BIOLINE RX LTD SPON ADR EACH REP 600 ORD SHS (P/S) - https://www.biolinerx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BLRX - Q0.13.49·4.280.13.82-0.01-0.311.236984.00  4.068  3.8022.40  2.300116:10:04Sep 2915 min RT 2¢

Recent Trades - Last 10 of 98
Time ETExPriceChangeVolume
16:10:04Q3.81-0.031
16:04:06Q3.81-0.031
16:00:02Q3.81-0.0329
16:00:02Q3.81-0.038
16:00:02Q3.81-0.033
16:00:02Q3.81-0.0326
16:00:02Q3.81-0.0326
15:50:41Q3.82-0.0250
15:49:48Q3.860.0221
15:33:09Q3.850.0170

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-09-29 07:00U:BLRXNews ReleaseBioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
2025-08-14 07:00U:BLRXNews ReleaseBioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-08-07 07:00U:BLRXNews ReleaseBioLineRx to Report Second Quarter 2025 Results on August 14, 2025
2025-05-27 07:00U:BLRXNews ReleaseBioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-20 07:00U:BLRXNews ReleaseBioLineRx to Report First Quarter 2025 Results on May 27, 2025
2025-03-31 07:00U:BLRXNews ReleaseBioLineRx Reports 2024 Financial Results and Provides Corporate Update
2025-01-21 07:00U:BLRXNews ReleaseBioLineRx Issues Letter to Shareholders
2025-01-17 07:00U:BLRXNews ReleaseBioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
2025-01-06 08:55U:BLRXNews ReleaseBioLineRx Announces $10 Million Registered Direct Offering
2024-11-25 07:00U:BLRXNews ReleaseBioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
2024-11-21 06:30U:BLRXNews ReleaseBioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA(TM) (motixafortide) through Gamida Cell Ltd.
2024-11-20 07:19U:BLRXNews ReleaseBioLineRx to Report Third Quarter 2024 Results on November 25, 2024
2024-11-05 09:00U:BLRXNews ReleaseBioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024